| dbo:abstract
|
- Nicholas B. Lydon (* 27. Februar 1957) ist ein US-amerikanischer Biochemiker und Geschäftsmann. (de)
- Nicholas B. Lydon, né le 27 février 1957, est un biochimiste et un homme d'affaires britannique. (fr)
- Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition. (en)
- 尼古拉斯·B·莱登（英語：Nicholas B. Lydon，1957年2月27日－），英国科学家、企业家。他因研发格列卫——一种治疗慢性粒细胞白血病的选择性BCR - ABL抑制剂获得2009年拉斯克奖。莱登在英国利兹大学获生物化学理学士，在邓迪大学获得博士学位。 (zh)
|
| dbo:almaMater
| |
| dbo:award
| |
| dbo:birthDate
| |
| dbo:institution
| |
| dbo:knownFor
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 8829 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:almaMater
|
- University of Dundee (en)
- University of Leeds (en)
- (en)
|
| dbp:awards
|
- (en)
- FRS (en)
- Japan Prize (en)
- Lasker Clinical Award (en)
|
| dbp:birthDate
| |
| dbp:knownFor
|
- (en)
- Gleevec (en)
- AnaptysBio (en)
- BluePrint Medicines (en)
|
| dbp:name
| |
| dbp:thesisTitle
|
- Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum (en)
|
| dbp:thesisUrl
| |
| dbp:thesisYear
| |
| dbp:wikiPageUsesTemplate
| |
| dbp:workplaces
|
- Amgen (en)
- Schering-Plough (en)
- (en)
- Ciba-Geigy (en)
|
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Nicholas B. Lydon (* 27. Februar 1957) ist ein US-amerikanischer Biochemiker und Geschäftsmann. (de)
- Nicholas B. Lydon, né le 27 février 1957, est un biochimiste et un homme d'affaires britannique. (fr)
- Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition. (en)
- 尼古拉斯·B·莱登（英語：Nicholas B. Lydon，1957年2月27日－），英国科学家、企业家。他因研发格列卫——一种治疗慢性粒细胞白血病的选择性BCR - ABL抑制剂获得2009年拉斯克奖。莱登在英国利兹大学获生物化学理学士，在邓迪大学获得博士学位。 (zh)
|
| rdfs:label
|
- Nicholas B. Lydon (de)
- Nicholas Lydon (fr)
- Nicholas Lydon (en)
- 尼古拉斯·莱登 (zh)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
